Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 419 articles:
HTML format
Text format



Single Articles


    August 2019
  1. DINGEMANS AC, Hendriks LEL, Berghmans T, Levy A, et al
    Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.
    J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655.
    PubMed     Text format     Abstract available


  2. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Through Host Toll-like Receptor 4 Activation.
    J Thorac Oncol. 2019 Aug 2. pii: S1556-0864(19)30653.
    PubMed     Text format     Abstract available


  3. STIRLING R, Zalcberg J
    Peeling the Onion of Health Care Disparity in Lung Cancer.
    J Thorac Oncol. 2019;14:e167-e168.
    PubMed     Text format    


  4. JAIN A, Fujioka N, Patel M
    Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
    J Thorac Oncol. 2019;14:e165-e167.
    PubMed     Text format    


  5. WATANABE Y, Kikuchi R, Iwai Y, Ito M, et al
    Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer.
    J Thorac Oncol. 2019;14:e163-e165.
    PubMed     Text format    


  6. ZHOU H, Liu J, Zhang Y, Huang Y, et al
    Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
    J Thorac Oncol. 2019;14:e161-e163.
    PubMed     Text format    


  7. ZWITTER M, Cufer T, Vrankar M, Kern I, et al
    Lung Cancer in Slovenia.
    J Thorac Oncol. 2019;14:1327-1331.
    PubMed     Text format    


  8. BERNICKER EH, Quigley EMM
    The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients - the Benefits of Diversity.
    J Thorac Oncol. 2019;14:1319-1322.
    PubMed     Text format    


    July 2019
  9. MAKIMOTO G, Ohashi K, Tomida S, Nishii K, et al
    Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden.
    J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602.
    PubMed     Text format     Abstract available


  10. YANG SC, Kuo CW, Lai WW, Lin CC, et al
    Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
    J Thorac Oncol. 2019 Jul 25. pii: S1556-0864(19)30588.
    PubMed     Text format     Abstract available


  11. CONDE E, Hernandez S, Martinez R, Angulo B, et al
    Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.
    J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562.
    PubMed     Text format     Abstract available


  12. EDELMAN MJ, Redman MW, Albain KS, McGary EC, et al
    Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557.
    PubMed     Text format     Abstract available


  13. BENITEZ JC, Mezquita L, Colle R, Tselikas KL, et al
    Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30556.
    PubMed     Text format    


  14. FUJINO T, Kobayashi Y, Suda K, Koga T, et al
    Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551.
    PubMed     Text format     Abstract available


  15. CANEPA M, Patel NR, Griffith RC, Ng TT, et al
    KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e153-e155.
    PubMed     Text format    


  16. WANG H, Zhang L, Liu W
    Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e141-e143.
    PubMed     Text format    


  17. HO C, Lefresne S, Liberman M, McGuire A, et al
    Lung Cancer in Canada.
    J Thorac Oncol. 2019;14:1128-1133.
    PubMed     Text format    


  18. FOSTER CC, Pitroda SP, Weichselbaum RR
    Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 1. pii: S1556-0864(19)30410.
    PubMed     Text format    


    June 2019
  19. BAUER TM, Besse B, Martinez-Marti A, Trigo JM, et al
    Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30503.
    PubMed     Text format     Abstract available


  20. NAITO T, Udagawa H, Sato J, Horinouchi H, et al
    A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30501.
    PubMed     Text format     Abstract available


  21. CHAE YK, Viveiros P, Lopes G, Sukhadia B, et al
    Clinical and immunological implications of frameshift mutations in lung cancer.
    J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496.
    PubMed     Text format     Abstract available


  22. MUNDEN RF, Chiles C, Boiselle PM, Sicks JD, et al
    Micronodules Detected on CT during the NLST: Prevalence and Relation to Positive Studies and Lung Cancer.
    J Thorac Oncol. 2019 Jun 20. pii: S1556-0864(19)30481.
    PubMed     Text format     Abstract available


  23. GUO R, Berry LD, Aisner DL, Sheren J, et al
    MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30474.
    PubMed     Text format     Abstract available


  24. BALATA H, Fong KM, Hendriks LE, Lam S, et al
    Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30476.
    PubMed     Text format     Abstract available


  25. BLACK WC, Chiles C, Church TR, Gareen IF, et al
    Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team (1).
    J Thorac Oncol. 2019 Jun 13. pii: S1556-0864(19)30473.
    PubMed     Text format     Abstract available


  26. IAMS WT, Shiuan E, Meador CB, Roth M, et al
    Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.
    J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463.
    PubMed     Text format     Abstract available


  27. AGGARWAL C, Redman MW, Lara PN Jr, Borghaei H, et al
    Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462.
    PubMed     Text format     Abstract available


  28. KIM Y, Kim CH, Lee HY, Lee SH, et al
    Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30454.
    PubMed     Text format     Abstract available


  29. LAIRD J, Lok BH, Carney B, Kossatz S, et al
    PET Imaging of a [(18)F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453.
    PubMed     Text format     Abstract available


  30. GIAJLEVRA N, Levra MG, Durieux V, Novello S, et al
    Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30458.
    PubMed     Text format     Abstract available


  31. GONG L, Qin J, Xie F, Han N, et al
    The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer.
    J Thorac Oncol. 2019;14:e120-e123.
    PubMed     Text format    


  32. JAZIEH AR, Algwaiz G, Alshehri SM, Alkattan K, et al
    Lung Cancer in Saudi Arabia.
    J Thorac Oncol. 2019;14:957-962.
    PubMed     Text format    


  33. ADJEI AA
    Lung Cancer Worldwide.
    J Thorac Oncol. 2019;14:956.
    PubMed     Text format    


  34. MILLER AB
    Improving Surveillance following Treatment for Lung Cancer.
    J Thorac Oncol. 2019;14:955.
    PubMed     Text format    


  35. RUTKOWSKI J, Saad ED, Burzykowski T, Buyse M, et al
    Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30415.
    PubMed     Text format     Abstract available


  36. SHEPSHELOVICH D, Xu W, Lu L, Fares A, et al
    Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30416.
    PubMed     Text format     Abstract available


    May 2019
  37. LANGER CJ, Redman MW, Wade JL 3rd, Aggarwal C, et al
    Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
    J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414.
    PubMed     Text format     Abstract available


  38. PARK S, Lee H, Lee B, Lee SH, et al
    DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30381.
    PubMed     Text format     Abstract available


  39. GOMEZ DR, Rimner A, Simone CB 2nd, Cho BCJ, et al
    The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applie
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30380.
    PubMed     Text format     Abstract available


  40. SPIGEL DR, McCleod M, Jotte RM, Einhorn L, et al
    Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged >/=70 Years or with Poor Performance Status (CheckMate 153).
    J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376.
    PubMed     Text format     Abstract available


  41. LEE Y, Kim TM, Kim DW, Kim S, et al
    Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30369.
    PubMed     Text format     Abstract available


  42. FLIPPOT R, Biondani P, Auclin E, Xiao D, et al
    Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30370.
    PubMed     Text format     Abstract available


  43. MURPHY SJ, Harris FR, Kosari F, Terra S, et al
    Using genomics to differentiate multiple primaries from metastatic lung cancer.
    J Thorac Oncol. 2019 May 16. pii: S1556-0864(19)30374.
    PubMed     Text format     Abstract available


  44. MUPPA P, Parrilha Terra SB, Sharma A, Mansfield AS, et al
    Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 9. pii: S1556-0864(19)30356.
    PubMed     Text format     Abstract available


  45. TREMBLAY A, Taghizadeh N, Huang J, Kasowski D, et al
    A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program.
    J Thorac Oncol. 2019 May 8. pii: S1556-0864(19)30359.
    PubMed     Text format     Abstract available


  46. CANNON-ALBRIGHT LA, Carr SR, Akerley W
    Population-based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.
    J Thorac Oncol. 2019 May 7. pii: S1556-0864(19)30316.
    PubMed     Text format     Abstract available


  47. VARGHESE C, Rajagopalan S, Karwoski RA, Bartholmai BJ, et al
    Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30355.
    PubMed     Text format     Abstract available


  48. THOMAS A, Vilimas R, Trindade C, Erwin-Cohen R, et al
    Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361.
    PubMed     Text format     Abstract available


  49. KATSUMATA S, Aokage K, Ishii G, Nakasone S, et al
    Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer.
    J Thorac Oncol. 2019 May 2. pii: S1556-0864(19)30313.
    PubMed     Text format     Abstract available


  50. MEHLMAN C, Chaabane N, Lacave R, Kerrou K, et al
    Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    J Thorac Oncol. 2019;14:e95-e96.
    PubMed     Text format    


  51. ZHANG J, Wang J, Qian Z, Han Y, et al
    CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
    J Thorac Oncol. 2019;14:e102-e103.
    PubMed     Text format    


  52. AHN MJ
    Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
    J Thorac Oncol. 2019;14:766-767.
    PubMed     Text format    


    April 2019
  53. JIN Y, Dong H, Xia L, Yang Y, et al
    The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30286.
    PubMed     Text format     Abstract available


  54. REMON J, Reguart N, Auclin E, Besse B, et al
    Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30202.
    PubMed     Text format    


  55. HUNG RJ, Spitz MR, Houlston RS, Schwartz AG, et al
    Lung Cancer Risk in Never Smokers of European Descent is Associated with Genetic Variation in the 5P15.33 TERT-CLPTM1L Region.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30289.
    PubMed     Text format     Abstract available


  56. DAI J, Liu M, Yang Y, Li Q, et al
    Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30290.
    PubMed     Text format     Abstract available


  57. MANOHARAN P, Salem A, Mistry H, Gornall M, et al
    [18F]fludeoxyglucose PET/CT in small-cell lung cancer: Analysis of the CONVERT randomized controlled trial.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30282.
    PubMed     Text format     Abstract available


  58. REMON J, Ahn MJ, Girard N, Johnson M, et al
    Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30280.
    PubMed     Text format     Abstract available


  59. SORICH MJ, Rowland A, Karapetis CS, Hopkins AM, et al
    Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
    J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285.
    PubMed     Text format     Abstract available


  60. MICHELS S, Massuti B, Schildhaus HU, Franklin J, et al
    Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.
    J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276.
    PubMed     Text format     Abstract available


  61. KRATZ JR, Haro GJ, Cook NR, He J, et al
    Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    J Thorac Oncol. 2019 Apr 5. pii: S1556-0864(19)30270.
    PubMed     Text format     Abstract available


  62. MEANEY C, Mitchell KA, Zingone A, Brown D, et al
    Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.
    J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269.
    PubMed     Text format     Abstract available


  63. LI C, Liang H, Zhong N, He J, et al
    Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.
    J Thorac Oncol. 2019;14:e82-e84.
    PubMed     Text format    


  64. QIN J, Wang J, Lin X, Wang J, et al
    Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e65-e68.
    PubMed     Text format    


  65. ARJYAL L
    Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e63.
    PubMed     Text format    


  66. LU S, Li Z
    Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:580-582.
    PubMed     Text format    


    March 2019
  67. BOUSEMA JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, et al
    Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2019 Mar 21. pii: S1556-0864(19)30211.
    PubMed     Text format    


  68. CAMIDGE DR, Dziadziuszko R, Peters S, Mok T, et al
    Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.
    J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210.
    PubMed     Text format     Abstract available


  69. OSAROGIAGBON RU, Veronesi G, Fang W, Ekman S, et al
    Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Mar 6. pii: S1556-0864(19)30199.
    PubMed     Text format     Abstract available


  70. LEE J, Maeng CH, Song JU
    The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019;14:e60-e61.
    PubMed     Text format    


  71. KOGURE Y, Ishii Y, Oki M
    Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    J Thorac Oncol. 2019;14:e55-e57.
    PubMed     Text format    


  72. LAM S
    Lung Cancer Screening in Never-Smokers.
    J Thorac Oncol. 2019;14:336-337.
    PubMed     Text format    


  73. FERRARA R, Caramella C, Besse B, Champiat S, et al
    Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
    J Thorac Oncol. 2019;14:328-331.
    PubMed     Text format    


  74. RAMAEKERS B, De Ruysscher D
    Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
    J Thorac Oncol. 2019;14:326-327.
    PubMed     Text format    


    February 2019
  75. DZIADZIUSZKO R, Smit EF, Dafni U, Wolf J, et al
    Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30148.
    PubMed     Text format     Abstract available


  76. SHUKUYA T, Yamada T, Koenig MJ, Xu J, et al
    The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30150.
    PubMed     Text format     Abstract available


  77. CAMIDGE DR, Kim EE, Usari T, Polli A, et al
    Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 26. pii: S1556-0864(19)30146.
    PubMed     Text format     Abstract available


  78. HENDRIKS LEL, Henon C, Auclin E, Mezquita L, et al
    Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117.
    PubMed     Text format     Abstract available


  79. NEGRAO MV, Lam VK, Reuben A, Rubin ML, et al
    PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30116.
    PubMed     Text format     Abstract available


  80. LIZEE T, Basch E, Tremolieres P, Voog E, et al
    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
    J Thorac Oncol. 2019 Feb 15. pii: S1556-0864(19)30113.
    PubMed     Text format     Abstract available


  81. AGGARWAL R, Lam AC, McGregor M, Menezes R, et al
    Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112.
    PubMed     Text format     Abstract available


  82. HSU WH, Zhao X, Zhu J, Kim IK, et al
    Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108.
    PubMed     Text format     Abstract available


  83. LEE JW, Zhang Y, Eoh KJ, Sharma R, et al
    The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111.
    PubMed     Text format     Abstract available


  84. ZIMMERMAN S, Das A, Wang S, Julian R, et al
    2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 11. pii: S1556-0864(19)30099.
    PubMed     Text format     Abstract available


  85. JEANSON A, Tomasini P, Souquet-Bressand M, Brandone N, et al
    Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040.
    PubMed     Text format     Abstract available


  86. EL OSTA B, Behera M, Kim S, Berry LD, et al
    Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30097.
    PubMed     Text format     Abstract available


  87. ZHAO X, Kallakury B, Chahine JJ, Hartmann D, et al
    Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30096.
    PubMed     Text format     Abstract available


  88. IJSSELDIJK MA, Shoni M, Siegert C, Wiering BM, et al
    Survival after SBRT for Clinically diagnosed or Biopsy-proven Early-stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019 Feb 2. pii: S1556-0864(19)30094.
    PubMed     Text format     Abstract available


  89. TABBO F, D'Aveni A, Tota D, Pignataro D, et al
    Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
    J Thorac Oncol. 2019;14:e38-e40.
    PubMed     Text format    


  90. VARKARIS A, Sehgal K, Rangachari D, Costa DB, et al
    Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
    J Thorac Oncol. 2019;14:e34-e36.
    PubMed     Text format    


  91. WATANABE K, Kage H, Shinozaki-Ushiku A, Kohsaka S, et al
    Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma.
    J Thorac Oncol. 2019;14:e31-e34.
    PubMed     Text format    


  92. BOGART JA, Mix M
    Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?
    J Thorac Oncol. 2019;14:153-156.
    PubMed     Text format    


    January 2019
  93. KIM ES, Roy UB, Ersek JL, King J, et al
    Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    J Thorac Oncol. 2019 Jan 29. pii: S1556-0864(19)30003.
    PubMed     Text format    


  94. RECK M, Horn L, Novello S, Barlesi F, et al
    Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029.
    PubMed     Text format     Abstract available


  95. TSENG CH, Tsuang BJ, Chiang CJ, Ku KC, et al
    The relationship between air pollution and lung cancer in non-smokers in Taiwan.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30026.
    PubMed     Text format     Abstract available


  96. DAGOGO-JACK I, Rooney M, Nagy RJ, Lin JJ, et al
    Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30027.
    PubMed     Text format     Abstract available


  97. PUJOL JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al
    A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025.
    PubMed     Text format     Abstract available


  98. DAGOGO-JACK I, Robinson H, Mino-Kenudson M, Farago AF, et al
    Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History.
    J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024.
    PubMed     Text format     Abstract available


  99. WU YL, Lu S, Cheng Y, Zhou C, et al
    Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.
    J Thorac Oncol. 2019 Jan 16. pii: S1556-0864(19)30020.
    PubMed     Text format     Abstract available


  100. QUINTANAL-VILLALONGA A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, et al
    FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30008.
    PubMed     Text format     Abstract available


  101. DAVIES KD, Lomboy A, Lawrence CA, Yourshaw M, et al
    Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30007.
    PubMed     Text format     Abstract available


  102. LU S, Yu Y, Li Z, Yu R, et al
    Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
    J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515.
    PubMed     Text format     Abstract available


  103. LEE YL, Hsu JF, Yang CJ
    Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e17-e18.
    PubMed     Text format    


  104. VAN LOON J, Dingemans AC
    Is Concurrent Chemoradiotherapy Also the Best Treatment for Elderly Patients with Limited-Stage Small Cell Lung Cancer? - What the CONVERT Data Can Tell Us.
    J Thorac Oncol. 2019;14:13-15.
    PubMed     Text format    


    December 2018
  105. PACHECO JM, Gao D, Smith D, Purcell WT, et al
    Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer.
    J Thorac Oncol. 2018 Dec 29. pii: S1556-0864(18)33533.
    PubMed     Text format     Abstract available


  106. YATABE Y, Dacic S, Borczuk AC, Warth A, et al
    Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
    J Thorac Oncol. 2018 Dec 17. pii: S1556-0864(18)33514.
    PubMed     Text format     Abstract available


  107. IAMS WT, Beckermann KE, Almodovar K, Hernandez J, et al
    Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS mutant lung adenocarcinoma: A report of two cases.
    J Thorac Oncol. 2018 Dec 10. pii: S1556-0864(18)33511.
    PubMed     Text format    


  108. SEIJO LM, Peled N, Ajona D, Boeri M, et al
    Biomarkers in lung cancer screening: achievements, promises and challenges.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33501.
    PubMed     Text format     Abstract available


  109. YANG JC, Gadgeel SM, Sequist LVD, Wu CL, et al
    Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33506.
    PubMed     Text format     Abstract available


    November 2018
  110. HECHTNER M, Eichler M, Wehler B, Buhl R, et al
    Quality of life in Non-Small Cell Lung Cancer survivors - a multicenter cross-sectional study.
    J Thorac Oncol. 2018 Nov 30. pii: S1556-0864(18)33497.
    PubMed     Text format     Abstract available


  111. SURESH K, Psoter KJ, Voong KR, Shankar B, et al
    Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33493.
    PubMed     Text format     Abstract available


  112. ERNANI V, Appiah AK, Marr A, Zhang C, et al
    Adjuvant Systemic Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT).
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33495.
    PubMed     Text format     Abstract available


  113. QU Y, Emoto K, Eguchi T, Aly RG, et al
    Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33494.
    PubMed     Text format     Abstract available


  114. LICHTENSTEIN M, Nipp RD, Muzikansky A, Goodwin K, et al
    Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454.
    PubMed     Text format     Abstract available


  115. KARACHALIOU N, Bracht JWP, Bruno MF, Drozdowskyj A, et al
    BRIEF REPORT: Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 22. pii: S1556-0864(18)33450.
    PubMed     Text format     Abstract available


  116. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.
    J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418.
    PubMed     Text format     Abstract available


  117. KANG HR, Cho JY, Lee SH, Lee YJ, et al
    Role of low-dose computerized tomography in lung cancer screening among never-smokers.
    J Thorac Oncol. 2018 Nov 13. pii: S1556-0864(18)33417.
    PubMed     Text format     Abstract available


  118. ZHANG C, Li SL, Nie Q, Dong S, et al
    Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33410.
    PubMed     Text format     Abstract available


  119. SINICROPI-YAO SL, Amann JM, Lopez DLY, Cerciello F, et al
    Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33411.
    PubMed     Text format     Abstract available


  120. BLAAUWGEERS H, Damhuis R, Lissenberg-Witte B, de Langen AJ, et al
    A population-based study of outcomes in surgically resected T3N0 non-small cell lung cancer in the Netherlands, defined using TNM-7 and TNM-8; justification of changes and an argument to incorporate histology in the staging algorithm?
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33413.
    PubMed     Text format     Abstract available


  121. SHIN DW, Cho J, Noh JM, Han H, et al
    Disparities in the diagnosis and treatment of lung cancer among people with disabilities.
    J Thorac Oncol. 2018 Nov 2. pii: S1556-0864(18)33407.
    PubMed     Text format     Abstract available


  122. RICCIUTI B, Marcomigni L, Metro G, Bellezza G, et al
    Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
    J Thorac Oncol. 2018;13:e220-e222.
    PubMed     Text format    


  123. YOSHIDA H, Ooi M, Kim YH
    Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    J Thorac Oncol. 2018;13:e219-e220.
    PubMed     Text format    


    October 2018
  124. KIM Y, Lee B, Shim JH, Lee SH, et al
    Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383.
    PubMed     Text format     Abstract available


  125. GELSOMINO F, Facchini G, Barbera MA, Lamberti G, et al
    Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33384.
    PubMed     Text format    


  126. SCHROCK AB, Welsh A, Chung JH, Pavlick D, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 24. pii: S1556-0864(18)33205.
    PubMed     Text format     Abstract available


  127. BASU ROY U, King-Kallimanis BL, Kluetz PG, Selig W, et al
    Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33052.
    PubMed     Text format    


  128. LAMMERS A, Slatore CG, Fromme EK, Vranas K, et al
    Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer : A National Cohort Study.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33184.
    PubMed     Text format    


  129. OKAMI J, Shintani Y, Okumura M, Ito H, et al
    Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint committee of Lung Cancer Registry database in 2010.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33180.
    PubMed     Text format     Abstract available


  130. READY N, Farago AF, de Braud F, Atmaca A, et al
    Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181.
    PubMed     Text format     Abstract available


  131. CHAE YK, Oh MS
    Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.
    J Thorac Oncol. 2018 Oct 5. pii: S1556-0864(18)33174.
    PubMed     Text format     Abstract available


  132. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173.
    PubMed     Text format     Abstract available


  133. LEVY A, Le Pechoux C, Mistry H, Martel-Lafay I, et al
    Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171.
    PubMed     Text format     Abstract available


  134. CHU X, Li Y, Zhu Z
    A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib.
    J Thorac Oncol. 2018;13:e211-e214.
    PubMed     Text format    


  135. TAKIGAWA N
    How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
    J Thorac Oncol. 2018;13:1438-1440.
    PubMed     Text format    


  136. SHOLL LM
    Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.
    J Thorac Oncol. 2018;13:1433-1435.
    PubMed     Text format    


    September 2018
  137. BLUMENTHAL GM, Bunn PA Jr, Chaft JE, McCoach CE, et al
    Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
    J Thorac Oncol. 2018 Sep 27. pii: S1556-0864(18)33129.
    PubMed     Text format    


  138. SURESH K, Voong KR, Shankar B, Forde PM, et al
    Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33118.
    PubMed     Text format     Abstract available


  139. QIN N, Li N, Wang C, Pu Z, et al
    Association of mosaic loss of chromosome Y with lung cancer risk and prognosis in a Chinese population.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33125.
    PubMed     Text format     Abstract available


  140. TOKI MI, Mani N, Smithy JW, Liu Y, et al
    Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33124.
    PubMed     Text format     Abstract available


  141. QIN A, Johnson A, Ross JS, Miller VA, et al
    Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33126.
    PubMed     Text format     Abstract available


  142. FRUH M M, Betticher DC, Stupp R, Xyrafas A, et al
    Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01).
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33123.
    PubMed     Text format     Abstract available


  143. TSAO AS, Lindwasser OW, Adjei AA, Adusumilli PS, et al
    Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation
    J Thorac Oncol. 2018 Sep 25. pii: S1556-0864(18)33121.
    PubMed     Text format     Abstract available


  144. DE RUYSSCHER D, Wanders R, Hendriks LE, van Baardwijk A, et al
    Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450).
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)30935.
    PubMed     Text format     Abstract available


  145. YU H, Chen Z, Ballman K, Watson MA, et al
    Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116.
    PubMed     Text format     Abstract available


  146. RAMALINGAM S, Dinan MA, Crawford J
    Survival comparison in patients with Stage IV lung cancer in Academic versus Community Centers in the United States.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33117.
    PubMed     Text format     Abstract available


  147. GANDARA DR, von Pawel J, Mazieres J, Sullivan R, et al
    Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043.
    PubMed     Text format     Abstract available


  148. SUN TY, Niu X, Chakraborty A, Neal JW, et al
    Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33046.
    PubMed     Text format    


  149. FERRER L, Giaj Levra M, Brevet M, Antoine M, et al
    A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044.
    PubMed     Text format     Abstract available


  150. LIN JJ, Chin E, Yeap BY, Ferris LA, et al
    Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
    PubMed     Text format     Abstract available


  151. DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
    Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
    PubMed     Text format     Abstract available


  152. DENG W, Xu T, Wang Y, Xu Y, et al
    Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
    PubMed     Text format     Abstract available


  153. LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
    Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
    PubMed     Text format     Abstract available


  154. SWAMI U, Smith M, Zhang J
    Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    J Thorac Oncol. 2018;13:e183-e184.
    PubMed     Text format    


  155. MO X, Xu-Welliver M
    Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e182-e183.
    PubMed     Text format    


  156. WALRAVEN I, Kwint M, Belderbos J
    The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e181-e182.
    PubMed     Text format    


  157. JIN B, Chuang X, Liu Y
    Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e174-e177.
    PubMed     Text format    


  158. DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
    Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    J Thorac Oncol. 2018;13:e169-e172.
    PubMed     Text format    


  159. XU YJ, Shi ZL, Wang Z, Du L, et al
    Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e165-e168.
    PubMed     Text format    


  160. MARINO M, Visca P, Ottaviano M
    PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
    J Thorac Oncol. 2018;13:1239-1241.
    PubMed     Text format    


    August 2018
  161. MORO M, Caiola E, Ganzinelli M, Zulato E, et al
    Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
    PubMed     Text format     Abstract available


  162. BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
    24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
    PubMed     Text format     Abstract available


  163. LAUFER-GEVA S, Rozenblum AB, Twito T, Grinberg R, et al
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    J Thorac Oncol. 2018 Aug 16. pii: S1556-0864(18)30940.
    PubMed     Text format     Abstract available


  164. GUAITOLI G, Baldessari C, Tomasello C, Barbieri F, et al
    Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    J Thorac Oncol. 2018;13:e152-e153.
    PubMed     Text format    


  165. FUJIOKA S, Kitajima T, Itotani R
    Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
    J Thorac Oncol. 2018;13:e137-e139.
    PubMed     Text format    


  166. GARCIA CA, Dacic S, Villaruz LC
    Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e135-e136.
    PubMed     Text format    


  167. HAMANN HA, Pujol JL
    Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma.
    J Thorac Oncol. 2018;13:1053-1054.
    PubMed     Text format    


    July 2018
  168. SU S, Dong ZY, Xie Z, Yan LX, et al
    Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811.
    PubMed     Text format     Abstract available


  169. ROACH MC, Robinson CG, DeWees TA, Ganachaud J, et al
    Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30812.
    PubMed     Text format     Abstract available


  170. ZHANG M, Wang Q, Ding Y, Wang G, et al
    Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 13. pii: S1556-0864(18)30785.
    PubMed     Text format     Abstract available


  171. KATO R, Hayashi H, Sano K, Handa K, et al
    Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer.
    J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30779.
    PubMed     Text format    


  172. OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
    Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
    PubMed     Text format     Abstract available


  173. RIESS JW, Gandara DR, Frampton GM, Madison R, et al
    Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
    PubMed     Text format     Abstract available


  174. WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
    A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
    PubMed     Text format     Abstract available


  175. PATIL T, Smith DE, Bunn PA, Aisner DL, et al
    The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
    PubMed     Text format     Abstract available


  176. SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
    Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
    PubMed     Text format    


  177. KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
    Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
    PubMed     Text format     Abstract available


  178. LIU Y, Lusk CM, Cho MH, Silverman EK, et al
    Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
    PubMed     Text format     Abstract available


  179. VELCHETI V, Madison R, Ali SM, Schrock AB, et al
    WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e122-e123.
    PubMed     Text format    


  180. ASSALLUM H, Harris K
    The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure.
    J Thorac Oncol. 2018;13:e119-e120.
    PubMed     Text format    


  181. NAVARRO A, Martinez-Marti A, Felip E
    HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
    J Thorac Oncol. 2018;13:874-876.
    PubMed     Text format    


    June 2018
  182. WU YL, Lu S, Lu Y, Zhou J, et al
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 29. pii: S1556-0864(18)30721.
    PubMed     Text format     Abstract available


  183. SHIUE K, Cerra-Franco A, Shapiro R, Estabrook N, et al
    Histology, tumor volume, and radiation dose predict outcomes in non-small cell lung cancer patients after stereotactic ablative radiotherapy.
    J Thorac Oncol. 2018 Jun 26. pii: S1556-0864(18)30716.
    PubMed     Text format     Abstract available


  184. LIN JJ, Zhu VW, Schoenfeld AJ, Yeap BY, et al
    Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
    J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714.
    PubMed     Text format     Abstract available


  185. WANG S, Yang L, Ci B, Maclean M, et al
    Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients.
    J Thorac Oncol. 2018 Jun 11. pii: S1556-0864(18)30687.
    PubMed     Text format     Abstract available


  186. HARATAKE N, Tagawa T, Hirai F, Toyokawa G, et al
    Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30681.
    PubMed     Text format    


  187. JONES CC, Mercaldo SF, Blume JD, Wenzlaff AS, et al
    Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682.
    PubMed     Text format     Abstract available


  188. ROLFO C, Mack PC, Scagliotti GV, Baas P, et al
    IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680.
    PubMed     Text format     Abstract available


  189. GERAUD A, Mezquita L, Bigot F, Caramella C, et al
    Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683.
    PubMed     Text format    


  190. PARK S, Ahn BC, Lim SW, Sun JM, et al
    Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673.
    PubMed     Text format     Abstract available


  191. YEGYA-RAMAN N, Wang K, Kim S, Reyhan M, et al
    Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675.
    PubMed     Text format     Abstract available


  192. WOZNIAK AJ, Schwartz AG
    Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
    J Thorac Oncol. 2018;13:e106-e107.
    PubMed     Text format    


  193. MASCALCHI M, Sali L
    Risk of Second Lung Cancer in ITALUNG LDCT Screening.
    J Thorac Oncol. 2018;13:e105-e106.
    PubMed     Text format    


  194. WU CK, Kao SJ, Lai HC
    Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
    J Thorac Oncol. 2018;13:e103-e105.
    PubMed     Text format    


  195. BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
    Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    J Thorac Oncol. 2018;13:748-751.
    PubMed     Text format    


  196. TSENG D, Padda SK, Wakelee HA
    Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:741-744.
    PubMed     Text format    


    May 2018
  197. GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
    Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
    PubMed     Text format     Abstract available


  198. HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
    Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
    J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
    PubMed     Text format     Abstract available


  199. FEHRENBACHER L, von Pawel J, Park K, Rittmeyer A, et al
    Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 16. pii: S1556-0864(18)30611.
    PubMed     Text format     Abstract available


  200. GADGEEL SM, Pennell NA, Fidler MJ, Halmos B, et al
    Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600.
    PubMed     Text format     Abstract available


  201. SPIGEL DR, Chaft JE, Gettinger S, Chao BH, et al
    FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603.
    PubMed     Text format     Abstract available


  202. WALTER JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, et al
    New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605.
    PubMed     Text format     Abstract available


  203. KARANTH S, Rajan SS, Sharma G, Yamal JM, et al
    Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study.
    J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540.
    PubMed     Text format     Abstract available


  204. CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
    Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
    PubMed     Text format     Abstract available


  205. SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
    Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
    PubMed     Text format     Abstract available


  206. NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
    Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
    PubMed     Text format     Abstract available


  207. KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
    Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
    PubMed     Text format     Abstract available


  208. VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
    The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
    PubMed     Text format     Abstract available


  209. GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
    Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
    PubMed     Text format     Abstract available


  210. TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
    Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
    PubMed     Text format    


  211. SAFIRI S, Ashrafi-Asgarabad A
    Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
    J Thorac Oncol. 2018;13:e85-e86.
    PubMed     Text format    


  212. WU B
    Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e84-e85.
    PubMed     Text format    


  213. HOYLE C, Dyer M
    Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e83-e84.
    PubMed     Text format    


  214. MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
    Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e77-e79.
    PubMed     Text format    


  215. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    "Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
    J Thorac Oncol. 2018;13:603-605.
    PubMed     Text format    


  216. HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
    Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
    J Thorac Oncol. 2018;13:601-602.
    PubMed     Text format    


  217. TANIZAKI J, Chiba Y, Haratani K, Hayashi H, et al
    In Reply.
    J Thorac Oncol. 2018;13:e86-e87.
    PubMed     Text format    


  218. RANGACHARI D, VanderLaan PA, Costa DB
    Updated Correlation of 22C3-PD-L1 >/=50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.
    J Thorac Oncol. 2018;13:e81-e83.
    PubMed     Text format    


  219. MIYAWAKI E, Murakami H, Takahashi T
    Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
    J Thorac Oncol. 2018;13:e79-e81.
    PubMed     Text format    


  220. ROSSI A, Novello S
    The Tradition of the Rising Sun: When Geography Counts.
    J Thorac Oncol. 2018;13:598-600.
    PubMed     Text format    


  221. HO C
    Anticipating the Next Step in the Management of ALK-Positive NSCLC.
    J Thorac Oncol. 2018;13:595-597.
    PubMed     Text format    


    April 2018
  222. DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
    BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
    J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
    PubMed     Text format     Abstract available


  223. ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
    The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
    PubMed     Text format     Abstract available


  224. VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
    Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
    PubMed     Text format    


  225. LI Z, Shen L, Ding D, Huang J, et al
    Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
    PubMed     Text format     Abstract available


  226. MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
    PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
    PubMed     Text format     Abstract available


  227. VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
    Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
    J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
    PubMed     Text format     Abstract available


  228. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
    PubMed     Text format     Abstract available


  229. WADE S, Weber M, Caruana M, Kang YJ, et al
    Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
    PubMed     Text format     Abstract available


  230. DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
    Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
    PubMed     Text format     Abstract available


  231. OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
    Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
    PubMed     Text format     Abstract available


  232. OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
    Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
    PubMed     Text format     Abstract available


  233. SANDBERG Y, den Bakker MA
    Small cell lung cancer presenting as carcinocythemia.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
    PubMed     Text format    


  234. MA Y, Zheng X, Zhao H, Fang W, et al
    First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
    PubMed     Text format     Abstract available


  235. CARR SR, Akerley W, Cannon-Albright L
    Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
    PubMed     Text format     Abstract available


  236. WATANABE J, Furuya N, Fujiwara Y
    Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
    J Thorac Oncol. 2018;13:e66-e69.
    PubMed     Text format    


  237. MORMILE R
    Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    J Thorac Oncol. 2018;13:e65-e66.
    PubMed     Text format    


  238. SAFIRI S
    Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
    J Thorac Oncol. 2018;13:e61.
    PubMed     Text format    


  239. SANDFELD-PAULSEN B, Aggerholm-Pedersen N
    Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
    J Thorac Oncol. 2018;13:e61-e62.
    PubMed     Text format    


  240. MASAI K, Motoi N
    Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
    J Thorac Oncol. 2018;13:e58-e59.
    PubMed     Text format    


  241. MANSORI K, Ayubi E, Safiri S
    Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2018;13:e57-e58.
    PubMed     Text format    


  242. SUN JM
    Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2018;13:e56-e57.
    PubMed     Text format    


  243. COSTANTINI A, Cadranel J
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e55-e56.
    PubMed     Text format    


  244. LEVY A, Hendriks LE, Faivre-Finn C
    Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
    J Thorac Oncol. 2018;13:475-477.
    PubMed     Text format    


  245. SENAN S, Rusthoven CG, Slotman BJ, Siva S, et al
    Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.
    J Thorac Oncol. 2018;13:488-496.
    PubMed     Text format     Abstract available


    March 2018
  246. GAJRA A, Zemla TJ, Jatoi A, Feliciano JL, et al
    Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients.
    J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254.
    PubMed     Text format     Abstract available


  247. LI Y, Liu B, Connolly ID, Kakusa BW, et al
    Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
    PubMed     Text format     Abstract available


  248. SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
    Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
    PubMed     Text format     Abstract available


  249. LEE CK, Lord S, Marschner I, Wu YL, et al
    The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
    J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
    PubMed     Text format     Abstract available


  250. FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
    Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
    PubMed     Text format     Abstract available


  251. GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
    Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
    PubMed     Text format     Abstract available


  252. MAENG CH, Song JU, Shim SR, Lee J, et al
    The Role of Prophylactic Cranial Irradiation in Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30180.
    PubMed     Text format     Abstract available


  253. PARRA ER, Villalobos P, Zhang J, Behrens C, et al
    Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30182.
    PubMed     Text format     Abstract available


  254. ROCCO G, Pennazza G, Santonico M, Longo F, et al
    Breathprinting and early diagnosis of lung cancer.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30183.
    PubMed     Text format     Abstract available


  255. SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
    Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
    PubMed     Text format     Abstract available


  256. TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
    A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
    J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
    PubMed     Text format     Abstract available


  257. YASUDA Y, Ozasa H, Kim YH
    PD-L1 Expression in Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e40-e41.
    PubMed     Text format    


  258. CHO JH, Sun JM, Lee SH, Ahn JS, et al
    Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e34-e36.
    PubMed     Text format    


  259. RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
    Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
    J Thorac Oncol. 2018;13:298-300.
    PubMed     Text format    


  260. FAN J, Dai X, Nie X
    Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    J Thorac Oncol. 2018;13:e45-e48.
    PubMed     Text format    


  261. YIN J, Zhang Y, Zhang Y, Peng F, et al
    Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
    J Thorac Oncol. 2018;13:e43-e45.
    PubMed     Text format    


  262. RIHAWI K, Cinausero M, Fiorentino M, Salvagni S, et al
    Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
    J Thorac Oncol. 2018;13:e41-e43.
    PubMed     Text format    


  263. RAEZ LE, Pinto JA, Schrock AB, Ali SM, et al
    EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
    J Thorac Oncol. 2018;13:e33-e34.
    PubMed     Text format    


    February 2018
  264. GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
    J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
    PubMed     Text format     Abstract available


  265. WEN J, Liu H, Wang L, Wang X, et al
    Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy.
    J Thorac Oncol. 2018 Feb 15. pii: S1556-0864(18)30103.
    PubMed     Text format     Abstract available


  266. VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
    Training and validating a portable electronic nose for lung cancer screening.
    J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
    PubMed     Text format     Abstract available


  267. EATON KD, Romine PE, Goodman GE, Thornquist MD, et al
    Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
    J Thorac Oncol. 2018 Feb 2. pii: S1556-0864(18)30090.
    PubMed     Text format     Abstract available


  268. MORGENSZTERN D, Samson P, Waqar SN, Devarakonda S, et al
    Early mortality in patients undergoing adjuvant chemotherapy for non-small-cell lung cancer.
    J Thorac Oncol. 2018 Feb 1. pii: S1556-0864(18)30036.
    PubMed     Text format     Abstract available


  269. ASHRAFI-ASGARABAD A, Safiri S
    Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2018;13:e26-e27.
    PubMed     Text format    


  270. LEONE A
    C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
    J Thorac Oncol. 2018;13:e21-e22.
    PubMed     Text format    


  271. GAZDAR AF
    Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    J Thorac Oncol. 2018;13:148-150.
    PubMed     Text format    


    January 2018
  272. KATZMAN D, Wu S, Sterman DH
    Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30079.
    PubMed     Text format     Abstract available


  273. WOLFF HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, et al
    Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30083.
    PubMed     Text format     Abstract available


  274. HUBBELING HG, Schapira EF, Horick NK, Goodwin KEH, et al
    Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jan 26. pii: S1556-0864(18)30039.
    PubMed     Text format     Abstract available


  275. STONE E, Jett J, Warren G, Cummings KM, et al
    Cannabis Use, Lung Cancer, and Related Issues.
    J Thorac Oncol. 2018 Jan 24. pii: S1556-0864(18)30038.
    PubMed     Text format     Abstract available


  276. LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
    J Thorac Oncol. 2018 Jan 23. pii: S1556-0864(17)33071.
    PubMed     Text format     Abstract available


  277. HOUSTON KA, Mitchell KA, King J, White A, et al
    Histologic Lung Cancer Incidence Rates and Trends vary by Race/Ethnicity and Residential County.
    J Thorac Oncol. 2018 Jan 19. pii: S1556-0864(18)30003.
    PubMed     Text format     Abstract available


  278. NYGARD L, Vogelius IR, Fischer BM, Kjaer A, et al
    A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006.
    PubMed     Text format     Abstract available


  279. MAROM EM, Ofek E, Bekker E, Onn A, et al
    Tattoo Induced False Positive FDG PET-CT Interpretation while Staging for Lung Cancer.
    J Thorac Oncol. 2018 Jan 17. pii: S1556-0864(18)30005.
    PubMed     Text format    


  280. RICCIUTI B, Metro G, Brambilla M, Ludovini V, et al
    Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.
    J Thorac Oncol. 2018;13:e9-e12.
    PubMed     Text format    


  281. MCCANN B, Clark B
    Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
    J Thorac Oncol. 2018;13:e7-e8.
    PubMed     Text format    


  282. ZHANG X, Zheng X
    Reply to "Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?"
    J Thorac Oncol. 2018;13:e16.
    PubMed     Text format    


  283. MORMILE R
    Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?
    J Thorac Oncol. 2018;13:e15.
    PubMed     Text format    


  284. DONG ZY, Zhang C, Li YF, Su J, et al
    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    J Thorac Oncol. 2018;13:85-96.
    PubMed     Text format     Abstract available


  285. BUCCIARELLI PR, Tan KS, Chudgar NP, Brandt W, et al
    BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    J Thorac Oncol. 2018;13:73-84.
    PubMed     Text format     Abstract available


  286. PATIL NS, Righi L, Koeppen H, Zou W, et al
    Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2018;13:124-133.
    PubMed     Text format     Abstract available


  287. NOONAN SA, Patil T, Gao D, King GG, et al
    Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
    J Thorac Oncol. 2018;13:134-138.
    PubMed     Text format     Abstract available


  288. SALVI S, Ravetti JL, Arena G, Musso C, et al
    Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.
    J Thorac Oncol. 2018;13:e12-e14.
    PubMed     Text format    


  289. AHN MJ
    Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
    J Thorac Oncol. 2018;13:10-11.
    PubMed     Text format    


    December 2017
  290. PILOTTO S, Sperduti I, Leuzzi G, Chiappetta M, et al
    Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33101.
    PubMed     Text format     Abstract available


  291. WU SP, Liao RQ, Tu HY, Wang WJ, et al
    Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33102.
    PubMed     Text format     Abstract available


  292. ROBIN TP, Camidge DR, Stuhr K, Nath SK, et al
    Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33107.
    PubMed     Text format     Abstract available


  293. MILLER ED, Fisher JL, Haglund KE, Grecula JC, et al
    The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33108.
    PubMed     Text format     Abstract available


  294. FELIP E, Barlesi F, Besse B, Chu Q, et al
    Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083.
    PubMed     Text format     Abstract available


  295. TSENG YH, Ho HL, Lai CR, Luo YH, et al
    Brief Report: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33079.
    PubMed     Text format     Abstract available


  296. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Influence of Ground-Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33080.
    PubMed     Text format     Abstract available


  297. STIEFEL F, Bourquin C
    Adverse Effects of "Teachable Moment" Interventions in Lung Cancer: Why Prudence Matters.
    J Thorac Oncol. 2017 Dec 11. pii: S1556-0864(17)32862.
    PubMed     Text format    


  298. STABILE LP, Farooqui M, Kanterewicz B, Abberbock S, et al
    Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33076.
    PubMed     Text format     Abstract available


  299. FUJIMOTO D, Sato Y, Uehara K, Ishida K, et al
    Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33072.
    PubMed     Text format     Abstract available


  300. HOTTA K, Aoe K, Kozuki T, Ohashi K, et al
    A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 4. pii: S1556-0864(17)33065.
    PubMed     Text format     Abstract available


  301. BOLZACCHINI E, Tuzi A, Gobba S, Pinotti G, et al
    Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
    J Thorac Oncol. 2017;12:e208-e210.
    PubMed     Text format    


  302. GU F, Cheung L, Katki H, Caporaso N, et al
    Response to Safiri et al. "Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening".
    J Thorac Oncol. 2017;12:e208.
    PubMed     Text format    


  303. SAFIRI S, Mansourpour H, Ayubi E
    Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers For Lung Cancer Screening.
    J Thorac Oncol. 2017;12:e207.
    PubMed     Text format    


  304. NAKANISHI Y, Masuda S, Iida Y, Takahashi N, et al
    Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    J Thorac Oncol. 2017;12:e202-e204.
    PubMed     Text format    



  305. Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
    J Thorac Oncol. 2017;12:1859.
    PubMed     Text format    


  306. WATZA D, Schwartz AG
    Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC.
    J Thorac Oncol. 2017;12:1744-1745.
    PubMed     Text format    


    November 2017
  307. SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
    Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33053.
    PubMed     Text format     Abstract available


  308. HENDRY S, Byrne DJ, Wright GM, Young RJ, et al
    Comparison of four PD-L1 immunohistochemical assays in lung cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33054.
    PubMed     Text format     Abstract available


  309. TANIZAKI J, Haratani K, Hayashi H, Chiba Y, et al
    Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab.
    J Thorac Oncol. 2017 Nov 20. pii: S1556-0864(17)33008.
    PubMed     Text format     Abstract available


  310. YANKELEVITZ DF
    CT Screening for Lung Cancer: Successful Trial, but Failed Understanding.
    J Thorac Oncol. 2017 Nov 18. pii: S1556-0864(17)32767.
    PubMed     Text format    


  311. RECK M, Taylor F, Penrod JR, DeRosa M, et al
    Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study.
    J Thorac Oncol. 2017 Nov 9. pii: S1556-0864(17)32878.
    PubMed     Text format     Abstract available


  312. FERRARA R, Auger N, Auclin E, Besse B, et al
    Clinical and translational implications of RET rearrangements in non-small cell lung cancer.
    J Thorac Oncol. 2017 Nov 8. pii: S1556-0864(17)32866.
    PubMed     Text format     Abstract available


  313. RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
    Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
    J Thorac Oncol. 2017;12:e184-e186.
    PubMed     Text format    


  314. LEE JS, Hur JY, Kim HJ, Lee KY, et al
    A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e179-e181.
    PubMed     Text format    


  315. HENNINGFIELD MF, Adjei AA
    Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
    J Thorac Oncol. 2017;12:1603-1605.
    PubMed     Text format    


    October 2017
  316. PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
    PubMed     Text format     Abstract available


  317. WU B, Gu X, Zhang Q
    Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
    PubMed     Text format     Abstract available


  318. SANDFELD-PAULSEN B, Meldgaard P, Aggerholm-Pedersen N
    Comorbidity in lung cancer: A prospective cohort study of self-reported versus register-based comorbidity.
    J Thorac Oncol. 2017 Oct 19. pii: S1556-0864(17)32788.
    PubMed     Text format     Abstract available


  319. PINATO DJ, Newsom-Davis T
    Regression of para-neoplastic rash following lung cancer chemotherapy.
    J Thorac Oncol. 2017 Oct 14. pii: S1556-0864(17)32786.
    PubMed     Text format    


  320. TOKACA N, Barth S, O'Brien M, Bhosle J, et al
    Molecular adequacy of image-guided rebiopsies for molecular retesting in advanced non-small cell lung cancer: a single centre experience.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32760.
    PubMed     Text format     Abstract available


  321. THAKUR MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, et al
    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology and End Results (SEER) Data.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32766.
    PubMed     Text format     Abstract available


  322. SHUKUYA T, Patel S, Shane-Carson K, He K, et al
    Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32764.
    PubMed     Text format    


  323. SHOLL LM
    Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.
    J Thorac Oncol. 2017;12:1464-1466.
    PubMed     Text format    


    September 2017
  324. SUN JM, Noh JM, Oh D, Kim HK, et al
    Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32708.
    PubMed     Text format     Abstract available


  325. MEYER M, Vliegenthart R, Henzler T, Buergy D, et al
    Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32713.
    PubMed     Text format     Abstract available


  326. BOYER MJ, Williams CD, Harpole DH, Onaitis MW, et al
    Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
    J Thorac Oncol. 2017 Sep 23. pii: S1556-0864(17)32706.
    PubMed     Text format     Abstract available


  327. ALMODOVAR K, Iams WT, Meador CB, Zhao Z, et al
    Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.
    J Thorac Oncol. 2017 Sep 22. pii: S1556-0864(17)32705.
    PubMed     Text format     Abstract available


  328. TERAOKA S, Fujimoto D, Morimoto T, Kawachi H, et al
    Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.
    J Thorac Oncol. 2017 Sep 19. pii: S1556-0864(17)30825.
    PubMed     Text format     Abstract available


  329. HIGGINS KA, Pillai RN, Chen Z, Tian S, et al
    Concomitant chemotherapy and radiotherapy with SBRT Boost for Unresectable, Stage III Non-small Cell Lung Cancer: A phase I Study.
    J Thorac Oncol. 2017 Sep 12. pii: S1556-0864(17)30734.
    PubMed     Text format     Abstract available


  330. GIMBRONE NT, Sarcar B, Gordian ER, Rivera JI, et al
    Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.
    J Thorac Oncol. 2017 Sep 11. pii: S1556-0864(17)30731.
    PubMed     Text format     Abstract available


  331. MASAI K, Sakurai H, Sukeda A, Suzuki S, et al
    Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30727.
    PubMed     Text format     Abstract available


  332. RUSTHOVEN CG, Kavanagh BD
    Prophylactic Cranial Irradiation (PCI) vs Active MRI Surveillance for Small-Cell Lung Cancer: The Case for Equipoise.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30728.
    PubMed     Text format     Abstract available


  333. SEPESI B, Correa AM, Dmitrovsky E, Liu X, et al
    Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".
    J Thorac Oncol. 2017;12:e150-e151.
    PubMed     Text format    


  334. SAFIRI S, Khazaei S, Ayubi E
    The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e149-e150.
    PubMed     Text format    


  335. KHUNGER M, Calabrese C, Kontzias A, Velcheti V, et al
    To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    J Thorac Oncol. 2017;12:e147-e149.
    PubMed     Text format    


  336. KOMATSU T, Nakamura K, Kawase A
    Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    J Thorac Oncol. 2017;12:e143-e144.
    PubMed     Text format    


  337. FUNAZO T, Nomizo T, Kim YH
    Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    J Thorac Oncol. 2017;12:e140-e141.
    PubMed     Text format    


  338. GORTAIS H, Daniel C, Bidard FC, Jeannot E, et al
    T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    J Thorac Oncol. 2017;12:e138-e139.
    PubMed     Text format    


  339. EZE C, Roengvoraphoj O, Manapov F
    Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.
    J Thorac Oncol. 2017;12:e137-e138.
    PubMed     Text format    


  340. VAN SCHIL PE
    Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?
    J Thorac Oncol. 2017;12:1338-1340.
    PubMed     Text format    


    August 2017
  341. WALD P, Mo X, Barney C, Gunderson D, et al
    Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30685.
    PubMed     Text format     Abstract available


  342. ARULANANDA S, Do H, Musafer A, Mitchell P, et al
    Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30681.
    PubMed     Text format     Abstract available


  343. DAVID EA, Clark JM, Cooke DT, Melnikow J, et al
    The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30683.
    PubMed     Text format     Abstract available


  344. GU F, Cheung LC, Freedman ND, Katki HA, et al
    Potential impact of including Time to First Cigarette into risk models for selecting ever-smokers for lung-cancer screening.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30664.
    PubMed     Text format     Abstract available


  345. LIN JJ, Shaw AT
    Recent Advances in Targeting ROS1 in Lung Cancer.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668.
    PubMed     Text format     Abstract available


  346. KONO M, Allen PK, Lin SH, Wei X, et al
    Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
    J Thorac Oncol. 2017 Aug 10. pii: S1556-0864(17)30661.
    PubMed     Text format     Abstract available


  347. XIZHAO S, Wei J, Haiqing C, Fan Y, et al
    Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.
    J Thorac Oncol. 2017 Aug 3. pii: S1556-0864(17)30659.
    PubMed     Text format     Abstract available


  348. SAFIRI S, Ayubi E
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e130-e131.
    PubMed     Text format    


  349. KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
    A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e128-e130.
    PubMed     Text format    


  350. YANAGISAWA S, Miyauchi E, Ichinose M
    Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
    J Thorac Oncol. 2017;12:e114-e116.
    PubMed     Text format    


  351. SHOJAEE S, Vachani A, Nana-Sinkam P
    The Financial Implications of Lung Cancer Screening: Is It Worth It?
    J Thorac Oncol. 2017;12:1177-1179.
    PubMed     Text format    


  352. STONE E, Slatore CG
    The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
    J Thorac Oncol. 2017;12:1174-1176.
    PubMed     Text format    


    July 2017
  353. FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
    Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
    PubMed     Text format    


  354. ZHANG X, Liu Y, Shao H, Zheng X, et al
    Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
    J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
    PubMed     Text format     Abstract available


  355. LI C, Huang C, Mok TS, Zhuang W, et al
    Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
    PubMed     Text format     Abstract available


  356. NORSKOV MS, Dahl M, Tybjaerg-Hansen A
    Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
    J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
    PubMed     Text format     Abstract available


  357. LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
    The current role of whole brain radiation therapy in non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
    PubMed     Text format     Abstract available


  358. CHO BC, Kim DW, Bearz A, Laurie SA, et al
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
    PubMed     Text format     Abstract available


  359. SHLOMI D, Abud M, Liran O, Bar J, et al
    Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
    J Thorac Oncol. 2017 Jul 11. pii: S1556-0864(17)30573.
    PubMed     Text format     Abstract available


  360. YANG JC, Ou SI, De Petris L, Gadgeel S, et al
    Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 5. pii: S1556-0864(17)30570.
    PubMed     Text format     Abstract available


  361. YOSHIDA R, Sasaki T, Ohsaki Y
    EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
    J Thorac Oncol. 2017;12:e92-e93.
    PubMed     Text format    


    June 2017
  362. GORE EM, Hu C, Sun AY, Grimm DF, et al
    Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937.
    J Thorac Oncol. 2017 Jun 22. pii: S1556-0864(17)30468.
    PubMed     Text format     Abstract available


  363. GUPTA A, Saltarski JM, White MA, Scaglioni PP, et al
    Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
    J Thorac Oncol. 2017 Jun 21. pii: S1556-0864(17)30466.
    PubMed     Text format     Abstract available


  364. BARON AE, Kako S, Feser WJ, Malinowski H, et al
    Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
    J Thorac Oncol. 2017 Jun 17. pii: S1556-0864(17)30461.
    PubMed     Text format     Abstract available


  365. EDELMAN MJ, Hu C, Le QT, Donington JS, et al
    Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839.
    J Thorac Oncol. 2017 Jun 16. pii: S1556-0864(17)30459.
    PubMed     Text format     Abstract available


  366. EVISON M, Clive A, Castle L, Powell H, et al
    Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
    J Thorac Oncol. 2017 Jun 14. pii: S1556-0864(17)30448.
    PubMed     Text format     Abstract available


  367. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Clinical and Pathological Staging Validation in the Eighth Edition of TNM Classification for Lung Cancer: Correlation Between Solid Size on Thin-section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.
    J Thorac Oncol. 2017 Jun 13. pii: S1556-0864(17)30444.
    PubMed     Text format     Abstract available


  368. SACHER AG, Komatsubara KM, Oxnard GR
    Application of plasma genotyping technologies in non-small cell lung cancer: a practical review.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30441.
    PubMed     Text format     Abstract available


  369. RANGACHARI D, Le X, Shea M, Huberman MS, et al
    Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30440.
    PubMed     Text format    


  370. LEVENTAKOS K, Peikert T, Midthun D, Molina JR, et al
    Management of multifocal lung cancer: Results of a survey.
    J Thorac Oncol. 2017 Jun 2. pii: S1556-0864(17)30421.
    PubMed     Text format     Abstract available


  371. CHIC N, Mayo-de-Las-Casas C, Reguart N
    Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    J Thorac Oncol. 2017;12:e78-e80.
    PubMed     Text format    


  372. HSU CL, Chen KY, Kuo SW, Chang YL, et al
    Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    J Thorac Oncol. 2017;12:e75-e76.
    PubMed     Text format    


  373. CHEN CW, Kuo CW, Chen YL, Ho CL, et al
    Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    J Thorac Oncol. 2017;12:e72-e74.
    PubMed     Text format    


  374. UGUEN A, Schick U, Quere G
    A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e71-e72.
    PubMed     Text format    


  375. THUNNISSEN E, Witte BI, Noguchi M, Yatabe Y, et al
    Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases."
    J Thorac Oncol. 2017;12:e70-e71.
    PubMed     Text format    


  376. SABOUR S
    Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer; Statistical Issue on Reproducibility Analysis.
    J Thorac Oncol. 2017;12:e69.
    PubMed     Text format    


  377. GREEN S, Dawe DE, Banerji S
    Immune Signatures of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:913-915.
    PubMed     Text format    


  378. FARUKI H, Mayhew GM, Serody JS, Hayes DN, et al
    Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    J Thorac Oncol. 2017;12:943-953.
    PubMed     Text format     Abstract available


  379. SHAIKH F, Zauderer MG, von Reibnitz D, Wu AJ, et al
    Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2017;12:993-1000.
    PubMed     Text format     Abstract available


  380. SCHROCK AB, Li SD, Frampton GM, Suh J, et al
    Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    J Thorac Oncol. 2017;12:932-942.
    PubMed     Text format     Abstract available


  381. VERRI C, Borzi C, Holscher T, Dugo M, et al
    Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
    J Thorac Oncol. 2017;12:922-931.
    PubMed     Text format     Abstract available


    May 2017
  382. SEPESI B, Gold KA, Correa AM, Heymach JV, et al
    The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30390.
    PubMed     Text format     Abstract available


  383. WAN R, Wang Z, Lee JJ, Wang S, et al
    Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30391.
    PubMed     Text format     Abstract available


  384. KARLSSON A, Brunnstrom H, Micke P, Veerla S, et al
    Gene expression profiling of large cell lung cancer links transcriptional phenotypes to the new histological WHO2015 classification.
    J Thorac Oncol. 2017 May 20. pii: S1556-0864(17)30388.
    PubMed     Text format     Abstract available


  385. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Text format     Abstract available


  386. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Text format     Abstract available


  387. ADAMS MN, Burgess JT, He Y, Gately K, et al
    Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
    J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
    PubMed     Text format     Abstract available


  388. GONG X, Li X, Jiang T, Xie H, et al
    Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
    PubMed     Text format     Abstract available


  389. MIYAUCHI E, Ichinose M, Inoue A
    Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
    J Thorac Oncol. 2017;12:e59-e61.
    PubMed     Text format    


  390. DAHELE M, Damhuis R
    The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
    J Thorac Oncol. 2017;12:e58-e59.
    PubMed     Text format    


  391. RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
    Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e51-e55.
    PubMed     Text format    


  392. OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
    Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e46-e47.
    PubMed     Text format    


  393. ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
    Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
    J Thorac Oncol. 2017;12:e45.
    PubMed     Text format    


  394. THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
    A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    J Thorac Oncol. 2017;12:804-813.
    PubMed     Text format     Abstract available


  395. ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
    Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
    J Thorac Oncol. 2017;12:890-896.
    PubMed     Text format     Abstract available


  396. RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
    Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:878-883.
    PubMed     Text format     Abstract available


  397. SAXON JA, Sholl LM, Janne PA
    EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    J Thorac Oncol. 2017;12:884-889.
    PubMed     Text format     Abstract available


  398. REULING EMBP, Dickhoff C, Daniels JMA
    Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
    J Thorac Oncol. 2017;12:e57-e58.
    PubMed     Text format    


  399. LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
    PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
    J Thorac Oncol. 2017;12:778-781.
    PubMed     Text format    


  400. SAVIC S, Rothschild S, Bubendorf L
    Lonely Driver ROS1.
    J Thorac Oncol. 2017;12:776-777.
    PubMed     Text format    


  401. BOTLING J, Sandelin M
    Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
    J Thorac Oncol. 2017;12:770-772.
    PubMed     Text format    


    April 2017
  402. CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
    The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
    PubMed     Text format     Abstract available


  403. RECK M, Blais N, Juhasz E, Gorbunova V, et al
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
    PubMed     Text format     Abstract available


  404. JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
    Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
    PubMed     Text format     Abstract available


  405. SOO RA, Adjei AA
    Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
    J Thorac Oncol. 2017;12:602-606.
    PubMed     Text format    


  406. GARDNER EE, Poirier JT, Rudin CM
    Histone Code Aberrancies in Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:599-601.
    PubMed     Text format    


  407. PETERS MLB, Costa DB, Rangachari D
    Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
    J Thorac Oncol. 2017;12:e35-e36.
    PubMed     Text format    


  408. LAINE A, Choy H
    Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
    J Thorac Oncol. 2017;12:610-611.
    PubMed     Text format    


  409. JOHN T, Russell PA, Thapa B
    Is Mesothelioma in China Rare or Misdiagnosed?
    J Thorac Oncol. 2017;12:607-609.
    PubMed     Text format    


    March 2017
  410. SENAN S, Louie AV
    Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
    J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
    PubMed     Text format    


  411. YANAGAWA N
    The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
    J Thorac Oncol. 2017;12:e25-e26.
    PubMed     Text format    


  412. MAO R, Chen C, Fei K
    The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:e24-e25.
    PubMed     Text format    


    February 2017
  413. WARTH A, Beasley MB, Mino-Kenudson M
    Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
    J Thorac Oncol. 2017;12:176-178.
    PubMed     Text format    


  414. HEIGENER DF, Reck M
    PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    J Thorac Oncol. 2017;12:171-172.
    PubMed     Text format    


    January 2017
  415. BASSE C, Merveilleux du Vignaux C, Girard N
    Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
    J Thorac Oncol. 2017;12:e8-e9.
    PubMed     Text format    


  416. RUSSO A, Franchina T, Ricciardi GRR, Adamo V, et al
    Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
    J Thorac Oncol. 2017;12:e6-e8.
    PubMed     Text format    


  417. LI YS, Jiang BY, Yang JJ, Tu HY, et al
    Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.
    J Thorac Oncol. 2017;12:e5-e6.
    PubMed     Text format    


  418. VENNIYOOR A
    False-Negative MRI Findings for Leptomeningeal Metastases with Use of Bevacizumab.
    J Thorac Oncol. 2017;12:e5.
    PubMed     Text format    


  419. SOLOMON B
    Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.
    J Thorac Oncol. 2017;12:9-11.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: